ASCO 2015 Highlights

Higher-Dose Daunorubicin Is Effective in Patients with AML Who Harbor FLT3-ITD Mutations

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Ibrutinib plus Bendamustine and Rituximab (BR) in Previously Treated CLL/SLL: 2-Year Follow-Up Data from the HELIOS Study

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Innovative Therapies in CLL: Saturday, June 11

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Length of Time on Treatment Observed in Ibrutinib Clinical Trials Is Reproducible After Assessment of Real-World Data

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Outcomes Associated with Conventional Salvage Therapy in Patients with Refractory or Relapsed AML and IDH1/IDH2 Mutations

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Overall Survival Benefit in Relapsed and Refractory B-Cell ALL Patients Receiving Inotuzumab Ozogamicin

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Presidential Symposium: Friday, June 10

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem-Cell Transplantation for De Novo ALL in Adults

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Response-Adapted Sequential Azacitidine and Intensive Chemotherapy Is Effective in Patients Aged >60 Years with Newly Diagnosed AML

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Valuable New Prognostic Scoring System in Patients with CML Receiving Nilotinib as Initial Treatment

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Page 162 of 329